FDAnews
www.fdanews.com/articles/73297-cephalon-announces-acquisition-of-trisenox-from-cell-therapeutics

Cephalon Announces Acquisition of Trisenox From Cell Therapeutics

June 13, 2005

Cephalon announced that it has signed an agreement with Cell Therapeutics and CTI Technologies a wholly owned subsidiary of Cell Therapeutics, under which it will acquire all assets related to Trisenox (arsenic trioxide) injection for approximately $70 million cash. The agreement provides for future cash payments to CTI, totaling up to $100 million, upon the achievement of certain label expansions and sales milestones.

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=20328420&full=1)